STAT2 siRNA lipid nanoparticles

STAT2 siRNA lipid nanoparticles are experimental RNA interference therapeutics designed to selectively downregulate signal transducer and activator of transcription 2 (STAT2) expression. Developed by researchers at Johns Hopkins University and the Université Libre de Bruxelles, these formulations utilize compositionally optimized lipid nanoparticles (LNPs), such as the B30 formulation, which can be conjugated to targeting ligands like the dipeptidyl peptidase-6 (DPP6)-targeting camelid nanobody 4hD29 (forming 4hD29-B30 LNPs) or the zinc transporter 8 (ZnT8)-targeting monoclonal antibody mAb43. This dual-targeting approach enables selective delivery of STAT2 siRNA to pancreatic beta cells, protecting them from interferon-alpha (IFN-α)-mediated deleterious effects and promoting protective PD-L1 expression, which holds therapeutic potential for the preservation of beta cell function in type 1 diabetes.

Other names

4hD29-B30 STAT2 siRNA lipid nanoparticlesB30 STAT2 siRNA lipid nanoparticlesB-30 STAT2 siRNA lipid nanoparticlesB 30 STAT2 siRNA lipid nanoparticlesSTAT2 siRNA LNPsSTAT-2 siRNA LNPsSTAT 2 siRNA LNPs